VEGFD and lymphangioleiomyomatosis: In this context, the Multicenter International Lymphangioleiomyomatosis Efficacy and Safety of Sirolimus (MILES) trial (McCormack et al, 2011) highlighted the clinical value of measuring basal serum levels of VEGF‐D as a disease biomarker (Young et al, 2013).